Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.
- Market Cap ₹ 1,238 Cr.
- Current Price ₹ 617
- High / Low ₹ 814 / 498
- Stock P/E 12.8
- Book Value ₹ 319
- Dividend Yield 0.29 %
- ROCE 22.3 %
- ROE 16.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 10.5% over past five years.
- Earnings include an other income of Rs.38.4 Cr.
- Dividend payout has been low at 4.11% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Healthcare BSE Allcap BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 192 | 208 | 223 | 311 | 304 | 325 | 353 | 376 | 423 | 472 | 510 | 581 | 597 | |
| 176 | 190 | 200 | 278 | 261 | 279 | 292 | 317 | 336 | 376 | 421 | 480 | 498 | |
| Operating Profit | 16 | 19 | 23 | 33 | 43 | 46 | 61 | 60 | 87 | 96 | 90 | 100 | 99 |
| OPM % | 8% | 9% | 10% | 11% | 14% | 14% | 17% | 16% | 21% | 20% | 18% | 17% | 17% |
| 5 | 1 | 5 | 6 | 2 | 6 | 6 | 12 | 6 | 10 | 22 | 34 | 38 | |
| Interest | 7 | 5 | 6 | 6 | 5 | 4 | 4 | 2 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 8 | 8 | 9 | 11 | 12 |
| Profit before tax | 11 | 13 | 19 | 30 | 36 | 43 | 58 | 64 | 84 | 96 | 100 | 122 | 124 |
| Tax % | 13% | 9% | 23% | 28% | 23% | 24% | 20% | 23% | 26% | 28% | 27% | 24% | |
| 10 | 11 | 15 | 22 | 27 | 33 | 47 | 50 | 62 | 69 | 73 | 93 | 97 | |
| EPS in Rs | 6.01 | 7.01 | 9.06 | 13.33 | 13.70 | 16.38 | 23.32 | 24.78 | 31.12 | 34.62 | 36.40 | 46.58 | 48.26 |
| Dividend Payout % | 10% | 9% | 11% | 8% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 11% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 15% |
| 3 Years: | 14% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 29% |
| 3 Years: | 25% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 73 | 83 | 95 | 115 | 170 | 200 | 243 | 284 | 346 | 413 | 482 | 573 | 619 |
| 61 | 51 | 48 | 61 | 53 | 56 | 34 | 5 | 1 | 2 | 2 | 1 | 1 | |
| 61 | 70 | 32 | 50 | 39 | 50 | 51 | 58 | 85 | 99 | 83 | 106 | 139 | |
| Total Liabilities | 211 | 220 | 192 | 242 | 282 | 326 | 347 | 367 | 452 | 534 | 587 | 700 | 780 |
| 33 | 32 | 33 | 63 | 68 | 83 | 88 | 91 | 111 | 132 | 151 | 179 | 177 | |
| CWIP | 2 | 2 | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 7 |
| Investments | 11 | 11 | 13 | 20 | 36 | 39 | 46 | 60 | 81 | 97 | 91 | 139 | 165 |
| 164 | 174 | 143 | 156 | 171 | 204 | 211 | 216 | 259 | 289 | 339 | 378 | 431 | |
| Total Assets | 211 | 220 | 192 | 242 | 282 | 326 | 347 | 367 | 452 | 534 | 587 | 700 | 780 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 9 | 9 | 29 | 18 | 21 | 51 | 71 | 69 | 76 | 39 | 63 | |
| -1 | 3 | -5 | -40 | -26 | -14 | -22 | -29 | -64 | -78 | -37 | -57 | |
| -1 | -17 | -5 | 11 | 8 | -4 | -30 | -38 | -6 | -3 | -4 | -5 | |
| Net Cash Flow | 2 | -5 | -1 | -0 | -0 | 4 | -1 | 4 | -1 | -4 | -2 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 139 | 152 | 135 | 88 | 95 | 108 | 117 | 88 | 97 | 89 | 97 | 101 |
| Inventory Days | 50 | 52 | 49 | 44 | 67 | 78 | 61 | 73 | 86 | 121 | 106 | 101 |
| Days Payable | 125 | 126 | 34 | 37 | 53 | 75 | 74 | 82 | 105 | 119 | 77 | 95 |
| Cash Conversion Cycle | 64 | 78 | 150 | 96 | 110 | 111 | 104 | 80 | 78 | 91 | 126 | 108 |
| Working Capital Days | 149 | 121 | 161 | 109 | 127 | 145 | 128 | 115 | 120 | 115 | 123 | 128 |
| ROCE % | 12% | 12% | 16% | 21% | 19% | 18% | 22% | 22% | 25% | 24% | 22% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Copies of newspaper intimation with respect to un-audited financial results for the quarter and half year ended on 30.09.2024.
- UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2024 14 Nov
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING
14 Nov - Board approved un-audited financial results for Q2 FY25.
-
Board Meeting Intimation for Consider And Approve The Un-Audited Financial Results For The Quarter Ended 30.09.2024.
5 Nov - Board meeting scheduled to approve Q2 financial results.
- Minutes Of 30Th Annual General Meeting Of The Company. 11 Oct
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jun 2024TranscriptNotesPPT
-
May 2024Transcript PPT REC
-
Feb 2024TranscriptNotesPPT
-
Oct 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
Apr 2021TranscriptNotesPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Apr 2020TranscriptNotesPPT
-
Jan 2020TranscriptNotesPPT
-
Oct 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Apr 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Oct 2018TranscriptNotesPPT
-
Jul 2018TranscriptNotesPPT
-
Apr 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Oct 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
Product Basket
Lincoln Pharma has developed 600+ formulations in 15 therapeutic areas. It has 1700 registered products and another 700 in the pipeline. Focus areas include anti-infective, respiratory system, gynecology, cardio & CNS, antidiabetic, anti-malaria among others. [1] During FY23, co. has launched 18 products in the domestic market and filled 130 plus dossiers in the export market.